Harvard Bioscience (HBIO) Total Liabilities (2010 - 2026)

Harvard Bioscience (HBIO) has reported Total Liabilities for 17 consecutive years, with $68.9 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Total Liabilities rose 7.0% year-over-year to $68.9 million in Q2 2026; TTM through Jun 2026 was $68.9 million, a 7.0% increase from a year earlier, with the FY2025 full-year figure at $66.3 million, up 4.79% from the prior year.
• Total Liabilities was $68.9 million for Q2 2026 at Harvard Bioscience, up from $67.9 million in the prior quarter.
• Over five years, Total Liabilities peaked at $81.7 million in Q1 2022 and troughed at $61.7 million in Q2 2024.
• A 5-year average of $68.2 million and a median of $66.1 million in 2024 frame the typical range for Total Liabilities.
• Across the five-year window, Total Liabilities climbed 10.16% in 2022 and fell 13.19% in 2023, its largest moves.
• Over 5 years, Total Liabilities stood at $73.1 million in 2022, then declined by 12.1% to $64.3 million in 2023, then decreased by 1.54% to $63.3 million in 2024, then rose by 4.79% to $66.3 million in 2025, then rose by 3.82% to $68.9 million in 2026.
• The last three Total Liabilities figures came in at $68.9 million (Q2 2026), $67.9 million (Q1 2026), and $66.3 million (Q4 2025), per Business Quant data.